Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators.

BACKGROUND The clinical and angiographic demographics of patients requiring unplanned coronary stent deployment and the optimal adjunct pharmacotherapy in this population are not well described. This report details the EPILOG trial experience with unplanned coronary stent deployment and the effect of abciximab platelet glycoprotein IIb/IIIa blockade to improve clinical outcomes during 6 months of follow-up. METHODS AND RESULTS After randomization in the EPILOG double-blind, placebo-controlled trial of abciximab therapy during percutaneous coronary intervention, 326 (12%) of 2792 patients required unplanned coronary stent deployment. Although stented patients were not distinguished by clinical variables, they had greater coronary lesion complexity by American Heart Association/American College of Cardiology criteria (P=.003) and greater incidence of lesion length >10 mm (P=.002), lesion eccentricity (P=.027), irregular lesion contour (P=.001), and bifurcation involvement (P=.019) than nonstented patients. Unplanned stents were required less often in patients treated with abciximab and low-dose, weight-adjusted heparin than in patients receiving placebo and standard-dose heparin (9.0% versus 13.7%; P=.001). Although adverse clinical outcomes including target-vessel revascularization and bleeding events were more frequent in patients requiring unplanned coronary stent deployment, abciximab therapy reduced adverse outcomes in these patients at 30 days and 6 months to a greater extent than was observed in patients not requiring stent placement. Among stented patients, abciximab therapy did not increase bleeding events. CONCLUSIONS Patients requiring unplanned coronary stent deployment have more complex coronary lesion morphology and a more complicated clinical course after coronary intervention. Abciximab therapy both reduces the need for unplanned stent deployment and confers clinical benefit to patients requiring an unplanned stent, without increasing bleeding complications.

[1]  Epic Investigators,et al.  Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. , 1994, The New England journal of medicine.

[2]  Thomas J. Ryan,et al.  Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Percutaneous Transluminal Coronary Angioplasty). , 1993, Journal of the American College of Cardiology.

[3]  M. Hadamitzky,et al.  Major benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary Palmaz-Schatz stent placement: analysis of a prospective risk stratification protocol in the Intracoronary Stenting and Antithrombotic Regimen (ISAR) trial. , 1997, Circulation.

[4]  D. Kereiakes,et al.  Partial reversal of heparin anticoagulation by intravenous protamine in abciximab-treated patients undergoing percutaneous intervention. , 1997, The American journal of cardiology.

[5]  J. Muhlestein,et al.  "Rescue" utilization of abciximab for the dissolution of coronary thrombus developing as a complication of coronary angioplasty. , 1997, Journal of the American College of Cardiology.

[6]  Thomas J. Ryan,et al.  Guidelines for Percutaneous Transluminal Coronary Angioplasty A Report of the American Heart Association/American College of Cardiology Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Percutaneous Transluminal Coronary Angioplasty) , 1993, Circulation.

[7]  B. Coller,et al.  In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. , 1997, Circulation.

[8]  W Rutsch,et al.  Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot Study. , 1996, Circulation.

[9]  M. Hadamitzky,et al.  Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy. , 1997, Journal of the American College of Cardiology.

[10]  Epilog Investigators,et al.  Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. , 1997, The New England journal of medicine.

[11]  A. Colombo,et al.  A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. , 1996, Circulation.

[12]  A. Branzi,et al.  Results of coronary stenting for unstable versus stable angina pectoris. , 1997, The American journal of cardiology.

[13]  R. Califf,et al.  Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial) , 1995 .

[14]  G. Roubin,et al.  Comparison of aspirin alone versus aspirin plus ticlopidine after coronary artery stenting. , 1996, The American journal of cardiology.

[15]  A. Kastrati,et al.  A RANDOMIZED COMPARISON OF ANTIPLATELET THERAPY AFTER THE PLACEMENT OF CORONARY ARTERY STENTS , 1996 .